Umeclidinium bromide

Umeclidinium bromide
Systematic (IUPAC) name

Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
Clinical data
Legal status	US: ℞-only
Identifiers
CAS Number	869113-09-7
ATC code	R03BB07 R03AL03 (+vilanterol)
PubChem	CID 11519069
ChemSpider	9693857
ChEBI	CHEBI:79040
Synonyms	GSK573719A
Chemical data
Formula	C₂₉H₃₄BrNO₂
Molar mass	508.49 g/mol
SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide is an anticholinergic drug approved for use in combination with vilanterol (as umeclidinium bromide/vilanterol) for the treatment of chronic obstructive pulmonary disease (COPD).^[1]^[2]

References

↑ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)^#/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol

Long-acting β₂ agonists (LABA)	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol Salmefamol

Ultra-long-acting β₂ agonists	Indacaterol Olodaterol Vilanterol

Other	Epinephrine^# Hexoprenaline Isoprenaline (isoproterenol) Orciprenaline (metaproterenol)

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast

Arachidonate 5-lipoxygenase inhibitors	Baicalein^§ Caffeic acid^§ Curcumin^§ Hyperforin^§ Meclofenamate sodium^§ St John's wort^§ Zileuton

Thromboxane receptor antagonists	Ramatroban Seratrodast

Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast

Others/unknown

Combination products

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, June 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.